Lipella Pharmaceuticals Inc. (LIPO) stock
Close on Oct 19, 2026Market cap $2.27KP/E –Yield –
Lipella Pharmaceuticals Inc. saw revenue fall 19.4% to $389.78K over the twelve months to Sep 30, 2025. At the latest close the market valued the company at $2.27K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2025
Valuation
- Market cap
- $2.27K
- P/E ratio
- –
- Price to sales
- 0.01
- Price to book
- 0.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $389.78K
- Net income
- -$5.33M
- EPS, diluted
- -$2.42
- Book value per share
- $0.33
- Diluted shares
- 5M
Trading
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 0
- Average volume (20 days)
- 1,506
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | LIPO | S&P 500 | Difference | LIPO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | -98.5% | +3.4% | −101.8 pts | ||
| Year to date | -99.7% | +13.3% | −113.0 pts | ||
| 1 year | -99.9% | +16.6% | −116.5 pts | ||
| 3 years | -100.0% | +86.4% | −186.4 pts | -96.6% | +23.1% |
Five years at a glance
Fiscal years 2020 to 2024 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lipella Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Lipella Pharmaceuticals
Pharmaceutical Preparations
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing therapies by reformulating existing generic active pharmaceutical ingredients. The company utilizes a proprietary metastable liposome drug delivery platform designed for local drug application to body cavities lined with endothelial and mucosal surfaces. Its product pipeline includes LP-10 for the treatment of hemorrhagic cystitis, LP-310 for oral lichen planus, LP-410 for oral graft-versus-host disease, and LP-50 for non-muscle invasive bladder cancer. These candidates target patients suffering from severe inflammatory mucosal conditions and treatment-related complications.
Company profile, executives and historyLipella Pharmaceuticals stock: common questions
What is Lipella Pharmaceuticals's stock price?
LIPO closed at $0.00 on Oct 19, 2026, up 0.00% on the day.
What is Lipella Pharmaceuticals's market cap?
Lipella Pharmaceuticals was worth $2.27K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is LIPO's P/E ratio?
Lipella Pharmaceuticals lost money over the twelve months to Sep 30, 2025 (diluted EPS -$2.42), so it has no meaningful P/E ratio.
How much revenue does Lipella Pharmaceuticals make?
Lipella Pharmaceuticals reported revenue of $389.78K for the twelve months to Sep 30, 2025, down 19.4% from a year earlier.
Does Lipella Pharmaceuticals pay a dividend?
No. Lipella Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has LIPO stock performed over the past year?
Including dividends, LIPO returned -99.9% over the past year, against +16.6% for the S&P 500.
Who are Lipella Pharmaceuticals's competitors?
Companies most similar to Lipella Pharmaceuticals by business, industry and size include CANF, SCNX, RGBP, PVCT, RDHL.
See a number that looks wrong?